Orelabrutinib, as a second-generation BTK inhibitor, has demonstrated potential efficacy in the treatment of CLL/SLL, MCL, and relapsed or refractory Waldenström's macroglobulinemia [25, 27, 36]. This evidence concerns the gene BTK and mantle cell lymphoma.